Hadacidin

Identification

Name
Hadacidin
Accession Number
DB02109  (EXPT01711)
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
External IDs
NSC-521778 / NSC-72962
Categories
UNII
BFO5P1010A
CAS number
Not Available
Weight
Average: 119.0761
Monoisotopic: 119.021857653
Chemical Formula
C3H5NO4
InChI Key
URJHVPKUWOUENU-UHFFFAOYSA-N
InChI
InChI=1S/C3H5NO4/c5-2-4(8)1-3(6)7/h2,8H,1H2,(H,6,7)
IUPAC Name
2-(N-hydroxyformamido)acetic acid
SMILES
ON(CC(O)=O)C=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UAdenylosuccinate synthetaseNot AvailableEscherichia coli (strain K12)
UAdenylosuccinate synthetase isozyme 1Not AvailableHuman
UAdenylosuccinate synthetase
inhibitor
Plasmodium falciparum
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Hadacidin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Hadacidin.Experimental
BevacizumabBevacizumab may increase the cardiotoxic activities of Hadacidin.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Hadacidin.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Hadacidin.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Hadacidin.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Hadacidin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Hadacidin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Hadacidin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Hadacidin.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Hadacidin.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Hadacidin.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Hadacidin.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Hadacidin.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Hadacidin.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Hadacidin.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Hadacidin.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Hadacidin.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Hadacidin.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Hadacidin.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
12717
PubChem Substance
46505891
ChemSpider
12194
BindingDB
50149248
ChEBI
43040
ChEMBL
CHEMBL331373
Therapeutic Targets Database
DNC000723
HET
HDA
PDB Entries
1cg0 / 1cg1 / 1cg3 / 1ch8 / 1cib / 1gim / 1gin / 1juy / 1kkb / 1kkf
show 6 more

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility50.0 mg/mLALOGPS
logP-0.97ALOGPS
logP-1.4ChemAxon
logS-0.38ALOGPS
pKa (Strongest Acidic)3.28ChemAxon
pKa (Strongest Basic)-5.9ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area77.84 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity22.72 m3·mol-1ChemAxon
Polarizability9.37 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.5771
Blood Brain Barrier+0.8934
Caco-2 permeable-0.646
P-glycoprotein substrateNon-substrate0.8403
P-glycoprotein inhibitor INon-inhibitor0.9501
P-glycoprotein inhibitor IINon-inhibitor0.9516
Renal organic cation transporterNon-inhibitor0.967
CYP450 2C9 substrateNon-substrate0.8383
CYP450 2D6 substrateNon-substrate0.8458
CYP450 3A4 substrateNon-substrate0.6561
CYP450 1A2 substrateNon-inhibitor0.8667
CYP450 2C9 inhibitorNon-inhibitor0.9039
CYP450 2D6 inhibitorNon-inhibitor0.8979
CYP450 2C19 inhibitorNon-inhibitor0.8601
CYP450 3A4 inhibitorNon-inhibitor0.8812
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9794
Ames testNon AMES toxic0.6094
CarcinogenicityNon-carcinogens0.5905
BiodegradationNot ready biodegradable0.7694
Rat acute toxicity2.0039 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9899
hERG inhibition (predictor II)Non-inhibitor0.9557
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as n-formyl-alpha amino acids. These are compounds containing an alpha amino acid which bears a formyl group at its terminal nitrogen atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
N-formyl-alpha amino acids
Alternative Parents
N-hydroxyl-alpha-amino acids / Hydroxamic acids / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
N-formyl-alpha-amino acid / N-hydroxyl-alpha-amino acid / Hydroxamic acid / Monocarboxylic acid or derivatives / Carboxylic acid / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Organic oxide / Hydrocarbon derivative
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
monocarboxylic acid, N-hydroxy amino acid, aldehyde (CHEBI:43040)

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Magnesium ion binding
Specific Function
Plays an important role in the de novo pathway of purine nucleotide biosynthesis. Catalyzes the first committed step in the biosynthesis of AMP from IMP.
Gene Name
purA
Uniprot ID
P0A7D4
Uniprot Name
Adenylosuccinate synthetase
Molecular Weight
47344.585 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Phosphate ion binding
Specific Function
Component of the purine nucleotide cycle (PNC), which interconverts IMP and AMP to regulate the nucleotide levels in various tissues, and which contributes to glycolysis and ammoniagenesis. Catalyz...
Gene Name
ADSSL1
Uniprot ID
Q8N142
Uniprot Name
Adenylosuccinate synthetase isozyme 1
Molecular Weight
50208.16 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Plasmodium falciparum
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Plays an important role in the salvage pathway for purine nucleotide biosynthesis. Catalyzes the first committed step in the biosynthesis of AMP from IMP (By similarity).
Gene Name
Adss
Uniprot ID
Q9U8D3
Uniprot Name
Adenylosuccinate synthetase
Molecular Weight
50064.525 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on June 13, 2005 07:24 / Updated on November 09, 2017 03:09